Skip to main content
. 2016 Dec 15;11(12):e0168552. doi: 10.1371/journal.pone.0168552

Fig 1.

Fig 1

Panel A: Serum levels of CC16 are increased in patients with IPF. The concentration of serum CC16 was measured in IPF (n = 85) and non-IPF patients [cHP (n = 85), CTD-ILD (n = 85)], and healthy controls (n = 30) using ELISA. All experiments were performed in duplicate. Panel B: Receiver operating characteristic (ROC) curves used to evaluate serum CC16 as a biomarker for IPF diagnosis.